x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

CME/CE

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD"s CME activities. Our topics span cardiology, diabetes, oncology, women"s health and more. And our CME library is continuously growing, every quarter.

science & medicine medicine

All Episodes

00:00:00

Managing Travel With PAH: Logistics, Medications,...

CME/CE ·

2025/07/15

Guest: Martha Kingman, DNP, FNP-C Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address

en

00:00:00

Treatment of a Broader Population of Patients With DMD

CME/CE ·

2025/07/14

Host: Crystal Proud, MD Guest: Erika Finanger, MD, MS By completing this activity, learners will gain the skills and confidence to determine therapeutic candidacy and conduct appropriate assessments for patients with Duchenne Muscular Dystrophy (DMD) across the age spectrum, including older and non-ambulatory individuals. They will improve their ability to interpret and apply the latest clinical data to real-world scenarios and make informed decisions about treatment and

en

00:00:00

Chairperson’s Perspective: Precision in Practice:...

CME/CE ·

2025/07/14

Host: Natasha B. Leighl, MD, MMSc This 30-minute Chairperson’s Perspective program explores the evolving landscape of (epidermal growth factor receptor) EGFR-altered metastatic non–small cell lung cancer through guideline-concordant, evidence-based learning. Dr. Natasha Leighl reviews the clinical importance and optimal timing of molecular testing and provides evidence-based strategies for patient selection and treatment sequencing across EGFR mutation subtypes, including common

en

00:00:00

Epilepsy: Beyond Seizure Impact

CME/CE ·

2025/07/09

Guest: Raman Sankar, MD, PhD Guest: Scott Aaronson, MD This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

en

00:00:00

Differentiating Neuromodulation Therapies: VNS, DBS,...

CME/CE ·

2025/07/09

Guest: Raman Sankar, MD, PhD Guest: Scott Aaronson, MD This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

en

00:00:00

QoL Matters: Brain Stem Stimulation in Patients With...

CME/CE ·

2025/07/09

Guest: Raman Sankar, MD, PhD Guest: Scott Aaronson, MD This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

en

00:00:00

VNS: Beyond Seizure Control

CME/CE ·

2025/07/09

Guest: Raman Sankar, MD, PhD Guest: Scott Aaronson, MD This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

en

00:00:00

Optimizing VNS Parameters: Keys to Therapeutic Success

CME/CE ·

2025/07/09

Guest: Raman Sankar, MD, PhD Guest: Scott Aaronson, MD This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

en

00:00:00

Stemming the Tide on MASLD/MASH: It Starts on the...

CME/CE ·

2025/07/08

Guest: Meena B. Bansal, MD, FAASLD Guest: Nicholas Pennings, DO, DABOM, MFOMA, FACOFP, FAAFP Guest: Fernando Bril, MD The epidemic of metabolic dysfunction-associated liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) is fully upon the US healthcare system, and it's projected to get worse. The prevalence of MASLD in the US is expected to increase from 33.7% in 2020 to 41.4% in 2050, which translates to approximately 122 million adults being

en

00:00:00

Pulmonary Hypertension: Getting the Right Diagnosis...

CME/CE ·

2025/07/03

Guest: Vallerie V. McLaughlin, MD Guest: Marsha Burks, BSN, RN Guest: Rajan Saggar, MD Pulmonary hypertension (PH) is a serious, progressive condition and the care pathways for patients who are living with Group 1 versus Group 2 PH can be very different. Join our experts as they discuss key elements for identifying which WHO Group your patient may fall into and review key factors for developing an effective treatment plan and knowing when to refer patients to other

en

00:00:00

Topline Results of the CONFIDENCE Trial

CME/CE ·

2025/06/07

Guest: Rajiv Agarwal, MBBS, MD, FASN, BRCU These video briefs feature expert commentary on the latest clinical data presented at ERA 2025 and highlight finerenone’s evolving role in the care of patients with the cardio-kidney-metabolic syndrome. Specialists discuss new findings from the CONFIDENCE trial and FINEARTS-HF trial, including the efficacy and safety of combining finerenone with SGLT2 inhibitors, finerenone’s impact on eGFR slope across albuminuria levels, and the prognostic

en

00:00:00

Albuminuria Change and Finerenone's Effect on CV...

CME/CE ·

2025/06/07

Guest: Finnian R. McCausland, MD These video briefs feature expert commentary on the latest clinical data presented at ERA 2025 and highlight finerenone’s evolving role in the care of patients with the cardio-kidney-metabolic syndrome. Specialists discuss new findings from the CONFIDENCE trial and FINEARTS-HF trial, including the efficacy and safety of combining finerenone with SGLT2 inhibitors, finerenone’s impact on eGFR slope across albuminuria levels, and the prognostic

en

00:00:00

Optimizing Barostim Outcomes: Practical Approaches to...

CME/CE ·

2025/06/06

Host: Cynthia J. Bither, ACNP-BC, MSN Guest: Andrea Wallace, MSN, FNP-C, HF-Cert Medical devices such as Barostim – or baroreflex activation therapy (BAT) – can play an important role in improving the quality of life and providing symptom relief for patients with heart failure with reduced ejection fraction, or HFrEF. NPs and nurses are key members of the healthcare team who identify patients as potential candidates for this therapy, due in large part to their expertise in

en

00:00:00

Enhancing Diagnosis, Treatment, and Outcomes in...

CME/CE ·

2025/04/25

Host: Carlos M. de Castro, MD Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by hemolytic anemia and associated with thrombophilia and bone marrow failure. Early and accurate diagnosis and classification of PNH is essential to optimize outcomes. However, the diagnosis of PNH may be delayed or missed for months or even years in practice, and only 25% of newly diagnosed patients receive any PNH-specific treatment. Moreover, up to 20% of patients

en

00:00:00

Second-line Chemotherapy Options in Metastatic PDAC

CME/CE ·

2025/04/16

Guest: Efrat Dotan, MD Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes, and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and

en

00:00:00

First-line Chemotherapy Options in Metastatic PDAC

CME/CE ·

2025/04/16

Guest: Eileen O’Reilly, MD Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes, and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies

en

00:00:00

Chairperson Perspective: Core Concepts for...

CME/CE ·

2025/04/15

Host: Tycel Phillips, MD Dr. Tycel Phillips presents a summary and offers expert insights on relevant and timely advances in bispecific antibody therapy for the treatment of R/R FL. The activity reviews topics including differentiating approved bispecific antibodies, evidence- and guideline-based treatment planning, patient selection, practical considerations, and optimizing safety in the application of bispecific antibody therapy in R/R FL.

en

00:00:00

Second-line Chemotherapy Options in Metastatic PDAC

CME/CE ·

2025/04/11

Guest: Efrat Dotan, MD Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes, and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and

en

00:00:00

First-line Chemotherapy Options in Metastatic PDAC

CME/CE ·

2025/04/11

Guest: Eileen O’Reilly, MD Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes, and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies

en

00:00:00

Revolutionizing Diagnostic Precision: AI-Driven...

CME/CE ·

2025/04/04

Guest: Marilyn Yuanxin Ma Bui, MD, PhD Guest: Anne Vincent-Salomon, MD With the availability of HER2-directed therapies, it’s important to accurately identify patients who would benefit from these therapies, particularly in breast cancer, where we now have a spectrum of HER2 positivity. Advances in technology have augmented the role of digital pathology (DP) and artificial intelligence (AI) in oncologic pathology. This activity demonstrates how DP/AI can be used for more accurate

en

245 results

Similar Podcasts

Eye On The Sky

Vermont Public

Cienciaes.com

cienciaes.com

This Week in Virology

Vincent Racaniello

Hablando con Científicos - Cienciaes.com

cienciaes.com

The Elective Rotation: A Critical Care Hospital Pharmacy Podcast

Pharmacy Joe